Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other brokerages have also recently issued reports on OTLK. Ascendiant Capital Markets decreased their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Chardan Capital reiterated a “buy” rating and set a $53.00 target price on shares of Outlook Therapeutics in a research note on Friday, August 16th. Finally, BTIG Research restated a “buy” rating and issued a $50.00 price target on shares of Outlook Therapeutics in a research note on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $48.20.

Outlook Therapeutics Price Performance

OTLK opened at $1.70 on Friday. The firm has a market cap of $40.22 million, a PE ratio of -0.16 and a beta of 0.62. The stock has a 50-day moving average price of $5.37 and a 200-day moving average price of $6.75. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Insider Buying and Selling at Outlook Therapeutics

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon purchased 5,000 shares of Outlook Therapeutics stock in a transaction dated Thursday, September 26th. The stock was purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares of the company’s stock, valued at $33,832.74. This trade represents a 528.54 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.40% of the stock is owned by corporate insiders.

Institutional Trading of Outlook Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OTLK. Christensen King & Associates Investment Services Inc. bought a new stake in shares of Outlook Therapeutics during the 3rd quarter valued at $55,000. AQR Capital Management LLC bought a new stake in Outlook Therapeutics during the second quarter valued at about $75,000. Barclays PLC increased its position in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after buying an additional 18,249 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Outlook Therapeutics in the third quarter worth about $199,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter valued at about $232,000. 11.20% of the stock is owned by hedge funds and other institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.